Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 2/20 | 0.47 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7061870 | 0.91 | CYP4F2 (0.49) | CYP4F2CYP4A11SMN1; SMN2FFAR4MEN1 | |
| SCHEMBL9157019 | 0.85 | CYP4F2 (0.64) | CYP4F2CYP4A11SMN1; SMN2CYP1A2CYP3A4 | |
| SCHEMBL12848923 | 0.82 | CYP4F2 (0.47) | CYP4F2CYP4A11SMN1; SMN2CYP1A2CYP3A4 | |
| SCHEMBL5964018 | 0.81 | CTDSP1 (0.48) | CYP4F2CYP4A11MEN1KMT2AALDH1A1 | |
| SCHEMBL11911407 | 0.79 | CYP4F2 (0.69) | CYP4F2CYP4A11SMN1; SMN2CYP1A2CYP3A4 | |
| SCHEMBL1511313 | 0.78 | CYP4F2 (0.69) | CYP4F2CYP4A11SMN1; SMN2CYP1A2CYP3A4 | |
| SCHEMBL1858472 | 0.78 | ALOX5 (0.56) | SMN1; SMN2 | |
| SCHEMBL7061469 | 0.77 | CYP4F2 (0.44) | CYP4F2CYP4A11SMN1; SMN2FFAR4MEN1 | |
| SCHEMBL7061467 | 0.77 | CYP4F2 (0.44) | CYP4F2CYP4A11SMN1; SMN2FFAR4MEN1 | |
| SCHEMBL5182214 | 0.76 | TAAR1 (0.47) | FFAR4KMT2ATAAR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6911444-B2 | Non-steroidal IL-5 inhibitors, processes and intermediates for their preparation and pharmaceutical compositions comprising said inhibitors | JANSSEN PHARMACEUTICS N.V. (BE) | 2005-06-28 | — | — | US | disclosed |
| US-20030114453-A1 | Non-steroidal IL-5 inhibitors, processes and intermediates for their preparation and pharmaceutical compositions comprising said inhibitors | JANSSEN PHARMACEUTICA, N.V. (BE) | 2003-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114453-A1 | Non-steroidal IL-5 inhibitors, processes and intermediates for their preparation and pharmaceutical compositions comprising said inhibitors | IL5, IL15, IL15RA | CYP4F2 298/4885CYP4A11 280/4885SMN1; SMN2 4150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.